EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

Abstract

The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. In view of this scenario, the European League Against Rheumatism (EULAR) promoted and supported an international collaborative study (EULAR SS Task Force) aimed at developing the first EULAR evidence and consensus-based recommendations for the management of patients with SjS with topical and systemic medications. The aim was to develop a rational therapeutic approach to SjS patients useful for healthcare professionals, physicians undergoing specialist training, medical students, the pharmaceutical industry and drug regulatory organisations following the 2014 EULAR standardised operating procedures. The Task Force (TF) included specialists in rheumatology, internal medicine, oral health, ophthalmology, gynaecology, dermatology and epidemiology, statisticians, general practitioners, nurses and patient representatives from 30 countries of the 5 continents. Evidence was collected from studies including primary SjS patients fulfilling the 2002/2016 criteria; when no evidence was available, evidence from studies including associated SjS or patients fulfilling previous sets of criteria was considered and extrapolated. The TF endorsed the presentation of general principles for the management of patients with SjS as three overarching, general consensus-based recommendations and 12 specific recommendations that form a logical sequence, starting with the management of the central triplet of symptoms (dryness, fatigue and pain) followed by the management of systemic disease. The recommendations address the use of topical oral (saliva substitutes) and ocular (artificial tear drops, topical non-steroidal anti-inflammatory drugs, topical corticosteroids, topical CyA, serum tear drops) therapies, oral muscarinic agonists (pilocarpine, cevimeline), hydroxychloroquine, oral glucocorticoids, synthetic immunosuppressive agents (cyclophosphamide, azathioprine, methotrexate, leflunomide and mycophenolate), and biological therapies (rituximab, abatacept and belimumab). For each recommendation, levels of evidence (mostly modest) and TF agreement (mostly very high) are provided. The 2019 EULAR recommendations are based on the evidence collected in the last 16 years in the management of primary 2002 SjS patients and on discussions between a large and broadly international TF. The recommendations synthesise current thinking on SjS treatment in a set of overarching principles and recommendations. We hope that the current recommendations will be broadly applied in clinical practice and/or serve as a template for national societies to develop local recommendations.

Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets

“…There exists a need to generate evidence regarding the role of such prophylactic therapy in COVID- 19. The e x a c t c l i n i c a l s c e n a r i o s w h e r e c h l o r o q u i n e o r hydroxychloroquine may be useful in COVID-19 remain to be ascertained, unlike their use in rheumatic diseases where their indications are widely understood [39].…”

Fitness for purpose of routinely recorded health data to identify patients with complex diseases: The case of Sjögren's syndrome

“…21 In order to strengthen the patient selection, we examined the use of certain medication known to be much used by pSS patients. 22 These are:…”

Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review

“…In the treatment of rheumatoid arthritis (RA), the use of HCQ is an option in combination with methotrexate and sulfasalazine for a guideline-based therapeutic strategy [2]. Recent EULAR recommendations name HCQ as a therapeutic option that can be considered for treating patients with primary Sjögren's syndrome or antiphospholipid syndrome under certain circumstances [3,4]. However, the two latter indications have so far not been approved in Germany.…”